Team
Leadership team
Leading NTA to exceed client expectations: results focused, science minded and quality driven.
Andy Barlow – CEO
Andy joined The Florey in 2023 with a comprehensive range of experience, including 27 years’ understanding of listed and non-listed businesses both as a Financial and Risk assurance Partner at PwC and as a CEO of a specialist cloud-based software implementation partner.
His well-rounded risk, compliance, problem-solving and reporting skills combine with a high degree of financial, commercial and strategic acumen to align the leadership and strategic initiatives of the NTA.
Adam Pirie – Business Development Manager
Adam joined NTA and The Florey in 2024, bringing with him a breadth of experience across pharmaceutical commercial operations, supply chain, regulatory and product development.
After gaining his PhD in pre-clinical drug discovery he has worked for organisations developing pre-clinical assets; built and managed the supply chains for organisations with products in market; and led market entry and initiatives to increase therapeutic access to patients. His technical and operational experience enable him to support the clinical and therapeutic development programs of NTA’s clients.
Quality
Enabling quality drug development at every step.
NTA is committed to ensuring the highest quality conduct of clinical studies. NTA strives to provide you with a service that fulfills the project scope, agreed costs, proposed timelines and achieves a high level of client satisfaction.
NTA is committed to:
— service excellence that meets, or exceeds your expectations
— compliance with applicable regualtions and GCP guidelines
— continuous customer focus and support
— continuous improvement of all our activities
Clinical operations
Facilitating world-class clinical trials in neuroscience and beyond.
Our clinical operations team have extensive clinical research knowledge to drive superior results.
